New combo aims to wipe out hidden cancer cells after chemo

This study tests whether two drugs, fruquintinib and tislelizumab, can control leftover cancer cells in people with colorectal cancer who have completed chemotherapy but still show signs of minimal residual disease (MRD) on a blood test. About 20 adults with stable disease will receive the combination to see if it is safe and can prevent the cancer from coming back. The goal is to manage the disease, not necessarily cure it.